SCHEMBL1883429

SCHEMBL1883429

Cc1ccc(C(=O)Nc2nc(-c3ccncc3)cs2)cc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.74
MPL P40238 1/20 0.71
ADORA3 P0DMS8 2/20 0.67
NPC1 O15118 3/20 0.65
RAB9A P51151 3/20 0.65
KDM4E B2RXH2 3/20 0.65
LMNA P02545 2/20 0.65
SMN1; SMN2 Q16637 1/20 0.65
ROCK1 Q13464 2/20 0.65
ROCK2 O75116 1/20 0.65
MAPT P10636 6/20 0.64
ALDH1A1 P00352 3/20 0.62
MEN1 O00255 2/20 0.62
KMT2A Q03164 2/20 0.62
ESR1 P03372 1/20 0.62
POLB P06746 1/20 0.62
ESR2 Q92731 1/20 0.62
HSD17B10 Q99714 1/20 0.62
SCD O00767 1/20 0.62
THRB P10828 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12248876 0.96 PARP1 (0.76) PARP1MPLADORA3NPC1RAB9A
SCHEMBL235190 0.93 KDM4E (0.70) MPLADORA3NPC1RAB9AKDM4E
SCHEMBL233522 0.89 SCD (0.78) PARP1ADORA3NPC1RAB9AKDM4E
SCHEMBL5733493 0.87 KDM4E (0.62) MPLADORA3NPC1RAB9AKDM4E
SCHEMBL5732893 0.87 KMT2A (0.67) MPLADORA3NPC1RAB9AKDM4E
SCHEMBL13357578 0.87 PARP1 (0.70) PARP1MPLADORA3RAB9AKDM4E
SCHEMBL2753872 0.86 LMNA (0.77) PARP1ADORA3NPC1RAB9AKDM4E
SCHEMBL1883572 0.86 PARP1 (0.92) PARP1MPLADORA3LMNAROCK1
SCHEMBL16607130 0.86 ALDH1A1 (0.79) PARP1MPLNPC1RAB9AKDM4E
SCHEMBL1881014 0.86 ADORA3 (0.82) PARP1ADORA3NPC1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110105436-A1 HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT AUCKLAND UNISERVICES LIMITED (NZ) 2011-05-05 US disclosed
US-20110105436-A1 HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT AUCKLAND UNISERVICES LIMITED (NZ) 2011-05-05 US disclosed
US-20110105436-A1 HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT AUCKLAND UNISERVICES LIMITED (NZ) 2011-05-05 US disclosed
EP-1558607-B1 COMPOSITIONS USEFUL AS INHIBITORS OF ROCK AND OTHER PROTEIN KINASES VERTEX PHARMA (US) 2010-05-05 EP disclosed
WO-2009114552-A1 HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2009-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105436-A1 HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT VHL, TP53, BECN1 PARP1 555/4885MPL 2711/4885ADORA3 3596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.